查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080399

心血管藥物市場：2026-2032年全球市場預測（依產品類型、療法、劑型、年齡層、適應症、最終用戶和通路分類）

Cardiovascular Drugs Market by Product Type, Therapy Type, Dosage Form, Age Group, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心血管藥物市場將成長至 2,555.7 億美元，複合年成長率為 7.16%。

主要市場統計數據
基準年 2025 1574.1億美元
預計年份：2026年 1682.6億美元
預測年份 2032 2555.7億美元
複合年成長率 (%) 7.16%

根據世界衛生組織（世衛組織）的數據，心血管疾病是全球首要死因，每年估計造成1,790萬人死亡，心血管藥物在全球公共衛生中持續扮演核心角色。高血壓、心臟衰竭、冠狀動脈疾病、血脂異常症、血栓症形成、心律不整以及糖尿病和慢性腎臟病等心血管代謝合併症的高發生率推動了對心血管藥物的需求。

該市場涵蓋了成熟的療法，例如降血壓藥、他汀類藥物、抗血小板藥物、抗凝血藥、利尿劑、 BETA阻斷劑、鈣離子通道阻斷劑和抗心律不整藥，以及針對心臟衰竭、血脂降低和發炎的新型藥物。隨著臨床指引日益強調早期風險檢測、聯合治療和以結果為導向的護理，心血管製藥公司在療效、安全性、依從性、可及性和真實世界數據（REW）的生成方面展開競爭。

心血管藥物市場的變革性變化

心血管醫學的發展趨勢正從控制症狀轉向預防、風險糾正和減少長期事件。美國心臟學會（ACC）、美國心臟協會（AHA）和歐洲心臟學會（ESC）等組織不斷修訂治療指南，持續鼓勵積極管理血壓、膽固醇、血栓風險和心臟衰竭的進展。

人工智慧（AI）的累積影響

人工智慧（AI）對心血管醫學領域的藥物發現、臨床開發、安全性監測和病人參與的影響日益顯著。 AI驅動的篩檢透過識別藥物標靶、預測分子特性、分析體學資料集以及更有效率地將患者與入組標準相匹配，有助於提高臨床試驗的可行性。

對關鍵區域的洞察

亞太地區擁有龐大的患者群體，高血壓和糖尿病盛行率不斷上升，保險覆蓋範圍不斷擴大，中國、印度、日本、韓國和澳洲等國的基層醫療可及性不斷提高，使其成為主要的成長引擎。北美地區仍然是高價值地區，這得益於先進的診斷技術、積極採納的指南、創新療法的廣泛應用以及強大的真實世界數據（REW）基礎設施。該地區心血管藥物的使用情況受慢性病管理、專科醫生處方和保險公司審核的影響。

關鍵群體特定見解

在東協地區，都市化、人口老化以及公共衛生投入的增加正在推動對心血管藥物的需求，而價格可承受性、廣泛的零售藥局覆蓋範圍以及可靠的分銷仍然是關鍵的成功因素。海灣合作理事會（GCC）市場的特點是糖尿病和肥胖症盛行率高、醫院基礎設施完善，以及政府主導的醫療保健轉型計劃，這些計劃強調慢性病篩檢、綜合護理和降低長期心血管代謝風險。

主要國家的概況

美國在心血管藥物創新、處方量、專科藥房的採納率以及真實世界數據（REW）的生成方面均處於主導地位。同時，加拿大在其公共醫療報銷體系中強調以指南為基礎的醫療。墨西哥和巴西代表拉丁美洲巨大的市場機遇，在這些地區，學名藥的可及性、公共採購以及不斷擴大的私人保險正在影響藥物的採納。英國、德國、法國、義大利和西班牙的特點是擁有完善的循環系統醫療保健網路、醫療技術評估體系、價格談判機制以及成熟的心血管疾病預防性藥物治療。另一方面，俄羅斯仍受到國內生產重點、報銷政策和醫院就診模式的影響。

為行業領導者提供的實用建議

產業領導者應優先考慮在臨床結果、用藥依從性、安全性和衛生經濟學等領域進行實證差異化。由於心血管藥物通常在競爭激烈的治療領域中競爭，因此真實世界數據、亞組結果、長期安全性證據以及與支付方相關的終點指標對於確保永續的市場進入至關重要。

調查方法

本執行摘要採用基於公開權威資訊來源的系統性二手研究途徑編寫。主要資訊來源包括世界衛生組織（WHO）的全球疾病負擔數據、主要循環系統學會的臨床指南、美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構的意見，以及經同行評審的心血管藥物治療證據。

結論

心血管藥物市場具有獨特的特徵，即持續的需求、激烈的競爭和不斷的臨床創新。高血壓、動脈粥狀硬化、心臟衰竭、心律不整和血栓症等疾病仍然給全球帶來沉重的負擔，因此，人們對有效、價格合理且易於獲取的藥物的長期需求顯而易見。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 心血管藥物市場：依產品類型分類

  • 抗心律不整藥物
  • 抗高血壓藥物
    • ACE抑制劑
    • 血管收縮素素受體拮抗劑
    • BETA阻斷劑
    • 鈣離子通道阻斷劑
    • 利尿劑
  • 抗凝血物
    • 直介面服抗凝血劑
    • 低分子量肝素
    • 維生素K拮抗劑
  • 強心配醣體
  • 降血脂藥物
    • 貝特類藥物
    • 菸鹼酸
    • PCSK9抑制劑
    • 他汀類藥物
  • 溶栓藥物
  • 血管擴張劑

第8章 心血管藥物市場：依治療類型分類

  • 聯合治療
  • 單藥治療

第9章：心血管藥物市場：以劑型分類

  • 藥片
  • 膠囊
  • 注射藥物
  • 口服液體藥物
  • 經皮貼劑

第10章 心血管藥物市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第11章 心血管藥物市場：依適應症分類

  • 高血壓
  • 高血脂症
  • 缺血性心臟疾病
  • 心臟衰竭
    • HFrEF
    • HFpEF
  • 心律不整
    • 心房顫動
    • 心室心律不整
  • 血栓栓塞性疾病
    • 深層靜脈栓塞症
    • 肺動脈栓塞
    • 預防中風

第12章 心血管藥物市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第13章 心血管藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 心血管藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 心血管藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 心血管藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Endo, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Krka, dd
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sandoz Group AG
  • Sanofi SA
  • Servier Laboratories
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA05198

The Cardiovascular Drugs Market is projected to grow by USD 255.57 billion at a CAGR of 7.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 157.41 billion
Estimated Year [2026] USD 168.26 billion
Forecast Year [2032] USD 255.57 billion
CAGR (%) 7.16%

Cardiovascular drugs remain central to global public health because cardiovascular disease is the world's leading cause of death, accounting for an estimated 17.9 million deaths annually, according to the World Health Organization. Demand is anchored by the high prevalence of hypertension, heart failure, coronary artery disease, dyslipidemia, thrombosis, arrhythmias, and cardiometabolic comorbidities such as diabetes and chronic kidney disease.

The market spans long-established therapies, including antihypertensives, statins, antiplatelets, anticoagulants, diuretics, beta blockers, calcium channel blockers, and antiarrhythmics, alongside newer drug classes targeting heart failure, lipid lowering, and inflammation. As clinical guidelines increasingly emphasize earlier risk detection, combination therapy, and outcomes-based care, cardiovascular drug manufacturers are competing on efficacy, safety, adherence, access, and real-world evidence generation.

Transformative Shifts in the Cardiovascular Drug Landscape

The cardiovascular drugs landscape is shifting from symptom control toward prevention, risk modification, and long-term event reduction. Updated treatment pathways from organizations such as the American College of Cardiology, American Heart Association, and European Society of Cardiology continue to reinforce aggressive management of blood pressure, cholesterol, thrombosis risk, and heart failure progression.

Patent expirations have expanded access to low-cost generics, while branded innovation is moving toward specialty lipid-lowering agents, novel anticoagulants, SGLT2 inhibitors for heart failure, mineralocorticoid receptor antagonists, and RNA-based therapies. At the same time, payers are demanding measurable clinical value, creating a more evidence-intensive environment for cardiovascular drug commercialization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing cardiovascular drug discovery, clinical development, safety monitoring, and patient engagement. AI-enabled screening can help identify drug targets, predict molecule properties, analyze omics datasets, and improve trial feasibility by matching patients to inclusion criteria more efficiently.

The cumulative impact is strongest where AI supports evidence generation rather than replaces clinical judgment. In cardiovascular care, validated algorithms can enhance risk stratification, medication adherence monitoring, pharmacovigilance signal detection, and real-world outcomes analysis. However, responsible deployment requires transparent model validation, bias mitigation, regulatory alignment, and secure use of patient data under frameworks such as HIPAA, GDPR, and good clinical practice standards.

Key Regional Insights

Asia-Pacific is a major growth engine due to large patient populations, rising hypertension and diabetes prevalence, expanding insurance coverage, and increasing access to primary care in countries such as China, India, Japan, South Korea, and Australia. North America remains a high-value region supported by advanced diagnostics, strong guideline adoption, broad use of innovative therapies, and extensive real-world evidence infrastructure, with cardiovascular drug utilization shaped by chronic disease management, specialty prescribing, and payer scrutiny.

Europe benefits from mature reimbursement systems, high cardiovascular screening rates, and strong regulatory oversight through the European Medicines Agency and national health technology assessment bodies. Latin America shows expanding demand for affordable antihypertensive, lipid-lowering, and antithrombotic medicines, though access varies by country and by public versus private coverage. The Middle East faces a rising cardiometabolic disease burden linked to obesity, diabetes, and lifestyle risk factors, while Africa's priorities include hypertension detection, essential medicine availability, affordability, and resilient supply chains for chronic cardiovascular therapy.

Key Group Insights

Within ASEAN, cardiovascular drug demand is supported by urbanization, aging populations, and growing public health investment, with affordability, retail pharmacy reach, and distribution reliability remaining decisive success factors. GCC markets are shaped by high diabetes and obesity prevalence, strong hospital infrastructure, and government-backed health transformation programs that favor chronic disease screening, integrated care, and long-term cardiometabolic risk reduction.

The European Union emphasizes evidence-based prescribing, pharmacovigilance, and cost-effectiveness, making market access dependent on robust clinical and economic data. BRICS countries combine large patient pools with expanding domestic manufacturing, government procurement, and price-sensitive access systems, increasing demand for both essential generics and selected innovative cardiovascular drugs. G7 markets lead in innovation adoption, specialty drug reimbursement, and cardiovascular outcomes research, while NATO member countries overlap with many high-income systems where supply security, domestic manufacturing capacity, and medicine resilience have become strategic priorities.

Key Country Insights

The United States leads in cardiovascular drug innovation, prescription volume, specialty uptake, and real-world evidence generation, while Canada emphasizes guideline-based care within publicly funded reimbursement structures. Mexico and Brazil represent important Latin American opportunities where access to generics, public procurement, and private insurance expansion influence adoption. The United Kingdom, Germany, France, Italy, and Spain are shaped by strong cardiology networks, health technology assessment, pricing negotiations, and established use of preventive cardiovascular pharmacotherapy, while Russia remains influenced by domestic production priorities, reimbursement policy, and hospital access patterns.

China and India are central to volume growth due to large hypertension and diabetes populations, expanding screening, public health programs, and strong generic manufacturing capabilities. Japan, Australia, and South Korea combine aging demographics with sophisticated reimbursement systems, high clinical standards, and broad use of evidence-based prescribing, supporting demand for both established cardiovascular therapies and newer treatments for heart failure, dyslipidemia, thrombosis prevention, and cardiometabolic risk management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-backed differentiation across clinical outcomes, adherence, safety, and health economics. Cardiovascular drugs often compete in crowded therapeutic classes, making real-world data, subgroup outcomes, long-term safety evidence, and payer-relevant endpoints essential for sustained access.

Manufacturers should strengthen lifecycle management through fixed-dose combinations, patient support programs, digital adherence tools, and differentiated formulations. Partnerships with providers, payers, pharmacies, and digital health firms can improve persistence in chronic therapy. Companies should also reinforce supply resilience for essential cardiovascular medicines while accelerating innovation in high-unmet-need segments such as heart failure, resistant hypertension, inherited lipid disorders, thrombosis prevention, and residual inflammatory risk.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available, authoritative sources. Key inputs include global disease burden data from the World Health Organization, clinical guidance from major cardiology societies, regulatory perspectives from agencies such as the U.S. FDA and European Medicines Agency, and peer-reviewed evidence on cardiovascular pharmacotherapy.

The analysis evaluates epidemiology, treatment guidelines, reimbursement dynamics, drug class evolution, regional access trends, technology adoption, and chronic disease management priorities. Insights are synthesized qualitatively to identify commercially relevant patterns without relying on unverified projections. The methodology emphasizes data triangulation, consistency across reputable sources, and practical interpretation for decision-makers in the cardiovascular drugs industry.

Conclusion

The cardiovascular drugs market is defined by a rare combination of durable demand, intense competition, and continuous clinical innovation. The persistent global burden of hypertension, atherosclerotic disease, heart failure, arrhythmia, and thrombosis ensures long-term need for effective, affordable, and accessible medicines.

Future leadership will depend on balancing broad access to essential generics with differentiated innovation in outcomes-driven therapies. Organizations that align clinical evidence, payer value, digital enablement, supply resilience, and regional access strategies will be best positioned to improve cardiovascular health outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiovascular Drugs Market, by Product Type

  • 7.1. Anti-Arrhythmics
  • 7.2. Anti-Hypertensives
    • 7.2.1. Ace Inhibitors
    • 7.2.2. Angiotensin Receptor Blockers
    • 7.2.3. Beta Blockers
    • 7.2.4. Calcium Channel Blockers
    • 7.2.5. Diuretics
  • 7.3. Anticoagulants
    • 7.3.1. Direct Oral Anticoagulants
    • 7.3.2. Low Molecular Weight Heparins
    • 7.3.3. Vitamin K Antagonists
  • 7.4. Cardiac Glycosides
  • 7.5. Lipid-Lowering Agents
    • 7.5.1. Fibrates
    • 7.5.2. Niacin
    • 7.5.3. PCSK9 Inhibitors
    • 7.5.4. Statins
  • 7.6. Thrombolytics
  • 7.7. Vasodilators

8. Cardiovascular Drugs Market, by Therapy Type

  • 8.1. Combination Therapy
  • 8.2. Monotherapy

9. Cardiovascular Drugs Market, by Dosage Form

  • 9.1. Tablets
  • 9.2. Capsules
  • 9.3. Injectables
  • 9.4. Oral Solutions
  • 9.5. Transdermal Patches

10. Cardiovascular Drugs Market, by Age Group

  • 10.1. Pediatric
  • 10.2. Adult
  • 10.3. Geriatric

11. Cardiovascular Drugs Market, by Indication

  • 11.1. Hypertension
  • 11.2. Hyperlipidemia
  • 11.3. Coronary Artery Disease
  • 11.4. Heart Failure
    • 11.4.1. HFrEF
    • 11.4.2. HFpEF
  • 11.5. Arrhythmia
    • 11.5.1. Atrial Fibrillation
    • 11.5.2. Ventricular Arrhythmias
  • 11.6. Thromboembolic Disorders
    • 11.6.1. Deep Vein Thrombosis
    • 11.6.2. Pulmonary Embolism
    • 11.6.3. Stroke Prevention

12. Cardiovascular Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Cardiovascular Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Cardiovascular Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Cardiovascular Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cardiovascular Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. Alembic Pharmaceuticals Limited
  • 18.3. Alkem Laboratories Limited
  • 18.4. Amgen Inc.
  • 18.5. Amneal Pharmaceuticals, Inc.
  • 18.6. Aspen Pharmacare Holdings Limited
  • 18.7. AstraZeneca plc
  • 18.8. Aurobindo Pharma Limited
  • 18.9. Bayer AG
  • 18.10. Biocon Limited
  • 18.11. Boehringer Ingelheim GmbH
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cipla Limited
  • 18.14. Daiichi Sankyo Company, Ltd.
  • 18.15. Dr. Reddy's Laboratories Ltd.
  • 18.16. Endo, Inc.
  • 18.17. GlaxoSmithKline PLC
  • 18.18. Glenmark Pharmaceuticals Limited
  • 18.19. Hikma Pharmaceuticals PLC.
  • 18.20. Intas Pharmaceuticals Ltd.
  • 18.21. Johnson & Johnson
  • 18.22. Krka, d. d.
  • 18.23. Lupin Limited
  • 18.24. Merck & Co., Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer, Inc.
  • 18.27. Sandoz Group AG
  • 18.28. Sanofi SA
  • 18.29. Servier Laboratories
  • 18.30. STADA Arzneimittel AG
  • 18.31. Sun Pharmaceutical Industries Limited
  • 18.32. Teva Pharmaceutical Industries Ltd.
  • 18.33. Viatris Inc.
  • 18.34. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CARDIOVASCULAR DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-ARRHYTHMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-ARRHYTHMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-ARRHYTHMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-HYPERTENSIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANGIOTENSIN RECEPTOR BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANGIOTENSIN RECEPTOR BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANGIOTENSIN RECEPTOR BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIURETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIURETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIURETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT ORAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIRECT ORAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIRECT ORAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LOW MOLECULAR WEIGHT HEPARINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LOW MOLECULAR WEIGHT HEPARINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LOW MOLECULAR WEIGHT HEPARINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC GLYCOSIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC GLYCOSIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC GLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIPID-LOWERING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIPID-LOWERING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIPID-LOWERING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIBRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIBRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIBRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NIACIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NIACIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NIACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PCSK9 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PCSK9 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PCSK9 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STATINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STATINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THROMBOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THROMBOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THROMBOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VASODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HFREF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HFREF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HFREF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HFPEF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HFPEF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HFPEF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARRHYTHMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARRHYTHMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARRHYTHMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VENTRICULAR ARRHYTHMIAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VENTRICULAR ARRHYTHMIAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VENTRICULAR ARRHYTHMIAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL THROMBOEMBOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL THROMBOEMBOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL THROMBOEMBOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL STROKE PREVENTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL STROKE PREVENTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL STROKE PREVENTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 260. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 264. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. GCC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. G7 CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 298. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 302. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 304. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 305. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 306. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 307. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. G7 CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. NATO CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 312. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 316. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 319. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 320. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 321. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. NATO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 350. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVES, 2018-2032 (USD MILLION)
  • TABLE 355. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 356. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY LIPID-LOWERING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 357. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 358. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 359. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 360. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 361. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2032 (USD MILLION)
  • TABLE 362. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, 2018-2032 (USD MILLION)
  • TABLE 363. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY THROMBOEMBOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 364. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 365. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 366. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2032 (US